Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Phase II Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)

NCT02365441 is registered in ClinicalTrials.gov with Australasian Gastro-Intestinal Trials Group as lead sponsor.

NCT NCT02365441
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02365441 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Phase II Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)
Lead sponsor
Australasian Gastro-Intestinal Trials Group
Phase
Phase 2
Overall status
Unknown status
Start date
June 30, 2015
Completion date
December 31, 2023
Enrollment
78 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal stromal tumour